191 research outputs found

    Universal Surface Engineering of Transition Metals for Superior Electrocatalytic Hydrogen Evolution in Neutral Water

    Get PDF
    The development of low-cost hybrid water splitting-biosynthetic systems that mimic natural photosynthesis to achieve solar-to-chemical conversion is of great promise for future energy demands, but often limited by the kinetically sluggish hydrogen evolution reaction (HER) on the surface of nonprecious transition metal catalysts in neutral media. It is thus highly desirable to rationally tailor the reaction interface to boost the neutral HER catalytic kinetics. Herein, we report a general surface nitrogen modification of diverse transition metals (e.g. iron, cobalt, nickel, copper, and nickel-cobalt alloy), accomplished by a facile low-temperature ammonium carbonate treatment, for significantly improved hydrogen generation from neutral water. Various physicochemical characterization techniques including synchroton X-ray absorption spectroscopy (XAS) and theory modeling demonstrate that the surface nitrogen modification does not change the chemical composition of the underlying transition metals. Notably, the resulting nitrogen-modified nickel framework (N-Ni) exhibits an extremely low overpotential of 64 mV at 10 mA cm-2, which is, to our knowledge, the best among those nonprecious electrocatalysts reported for hydrogen evolution at pH 7. Out combined experimental results and density functional theory (DFT) calculations reveal that the surface electron-rich nitrogen simultaneously facilitates the initial adsorption of water via the electron-deficient H atom and the subsequent dissociation of the electron-rich HO-H bond via H transfer to N on the nickel surface, beneficial to the overall hydrogen evolution process

    Intravenous bone marrow mononuclear cells transplantation in aged mice increases transcription of glucose transporter 1 and Na+/K+-ATPase at hippocampus followed by restored neurological functions

    Get PDF
    We recently reported that intravenous bone marrow mononuclear cell (BM-MNC) transplantation in stroke improves neurological function through improvement of cerebral metabolism. Cerebral metabolism is known to diminish with aging, and the reduction of metabolism is one of the presumed causes of neurological decline in the elderly. We report herein that transcription of glucose transporters, monocarboxylate transporters, and Na+/K+-ATPase is downregulated in the hippocampus of aged mice with impaired neurological functions. Intravenous BM-MNC transplantation in aged mice stimulated the transcription of glucose transporter 1 and Na+/K+-ATPase Ξ±1 followed by restoration of neurological function. As glucose transporters and Na+/K+-ATPases are closely related to cerebral metabolism and neurological function, our data indicate that BM-MNC transplantation in aged mice has the potential to restore neurological function by activating transcription of glucose transporter and Na+/K+-ATPase. Furthermore, our data indicate that changes in transcription of glucose transporter and Na+/K+-ATPase could be surrogate biomarkers for age-related neurological impairment as well as quantifying the efficacy of therapies

    Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells

    Get PDF
    Defects in epigenetic pathways are key drivers of oncogenic cell proliferation. We developed a LSD1/HDAC6 multitargeting inhibitor (iDual), a hydroxamic acid analogue of the clinical candidate LSD1 inhibitor GSK2879552. iDual inhibits both targets with IC50 values of 540, 110, and 290 nM, respectively, against LSD1, HDAC6, and HDAC8. We compared its activity to structurally similar control probes that act by HDAC or LSD1 inhibition alone, as well as an inactive null compound. iDual inhibited the growth of leukemia cell lines at a higher level than GSK2879552 with micromolar IC50 values. Dual engagement with LSD1 and HDAC6 was supported by dose dependent increases in substrate levels, biomarkers, and cellular thermal shift assay. Both histone methylation and acetylation of tubulin were increased, while acetylated histone levels were only mildly affected, indicating selectivity for HDAC6. Downstream gene expression (CD11b, CD86, p21) was also elevated in response to iDual treatment. Remarkably, iDual synergized with doxorubicin, triggering significant levels of apoptosis with a sublethal concentration of the drug. While mechanistic studies did not reveal changes in DNA repair or drug efflux pathways, the expression of AGPAT9, ALOX5, BTG1, HIPK2, IFI44L, and LRP1, previously implicated in doxorubicin sensitivity, was significantly elevated

    Molecular Mixed-Metal Manganese Oxido Cubanes as Precursors to Heterogeneous Oxygen Evolution Catalysts

    Get PDF
    Well-defined mixed-metal [CoMn_3O_4] and [NiMn_3O_4] cubane complexes were synthesized and used as precursors for heterogeneous oxygen evolution reaction (OER) electrocatalysts. The discrete clusters were dropcasted onto glassy carbon (GC) and indium tin oxide (ITO) electrodes, and the OER activities of the resulting films were evaluated. The catalytic surfaces were analyzed by various techniques to gain insight into the structure-function relationships of the electrocatalysts’ heterometallic composition. Depending on preparation conditions, the Co-Mn oxide was found to change metal composition during catalysis, while the Ni–Mn oxides maintained the NiMn_3 ratio. XAS studies provided structural insights indicating that the electrocatalysts are different from the molecular precursors, but that the original NiMn_3O_4 cubane-like geometry was maintained in the absence of thermal treatment (2-Ni). In contrast, the thermally generated 3-Ni develops an oxide-like extended structure. Both 2-Ni and 3-Ni undergo structural changes upon electrolysis, but they do not convert into the same material. The observed structural motifs in these heterogeneous electrocatalysts are reminiscent of the biological oxygen-evolving complex in Photosystem II, including the MMn_3O_4 cubane moiety. The reported studies demonstrate the use of discrete heterometallic oxide clusters as precursors for heterogeneous water oxidation catalysts of novel composition and the distinct behavior of two sets of mixed metal oxides

    Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease

    Get PDF
    Highlights: Targeting single mechanisms of physiological (aging) and pathological (neurodegeneration) loss of function in the brain may not be sufficient. Cell–cell interactions between transplanted adult stem cells and resident cells via gap junctions have the potential to support the aging or diseased brain. These cell–cell interactions can also increase hippocampal neurogenesis. This may be a novel therapeutic strategy for Alzheimer's disease and other neurodegenerative diseases that could be applied alongside any established treatments

    Multitargeting epi-epi drugs for multidrug reistance

    Get PDF
    Epigenetic therapy is now a clinical reality with eight approved drugs that target DNA methyltransferases, histone deacetylases (HDACs) and lysine methyltransferases. A further recent development is the concept of epigenetic multitargeting through the rational design of novel agents that combine the inhibition of an epigenetic pathway with a second non-epigenetic target and five such compounds have advanced to clinical development. We are investigating the even newer concept of β€žepi-epiβ€Ÿ drugs that inhibit two separate epigenetic pathways. Such dual targeting agents have the potential to achieve higher efficacy against proliferating cancer cells while reducing tunor resistance. In this presentation, we report a selective dual histone deacetylase and demethylase inhibitor with an IC50 LSD1 respectively. The compound was biologically profiled together with control compounds that were either single inhibitors or inactive against either enzyme. The dua inhibitor was active against a panel of leukemia cell lines at a micromolar level and induced apoptosis. Target engagement asays such as CETSA were employed to confirm the inhibition of HDAC6 and LSD1 in cells. Further experiments were carried out to identify synergistic effects with clinically approved agents and promising results were observed with doxorubicin

    ΠŸΠΎΡΡ‚ΠΎΡ˜ΠΈ Π»ΠΈ Π³Ρ€Π°Π½ΠΈΡ†Π° ΠΈΠ·ΠΌΠ΅Ρ’Ρƒ цитотоксичног ΠΈ антимСтастатског Π΅Ρ„Π΅ΠΊΡ‚Π° сСлСктивних ΠΈΠ½Ρ…ΠΈΠ±ΠΈΡ‚ΠΎΡ€Π° хистон Π΄Π΅Π°Ρ†Π΅Ρ‚ΠΈΠ»Π°Π·Π΅ 6 ΠΊΠΎΠ΄ солидних Ρ‚ΡƒΠΌΠΎΡ€Π°?

    Get PDF
    Academia and industry make an extensive effort to discover selective histone deacetylase 6 inhibitors (HDAC6i) which could be delivered to the patients. These attempts are partially obscured by inconsistency in preclinical data regarding the cellular and biochemical changes upon treatment of solid tumours with HDAC6i. In this study, we present computational design, synthesis of three novel HDAC6 inhibitors along with their in vitro pharmacological profile against zinc-dependent HDACs. The in vitro anticancer effects of the synthesized compounds were examined on four types of cancer cell lines, human breast cancer cell lines (MDA-MB-231 and MCF-7) as well as human melanoma cells (A-375 and 518A2). It was found that the synthesized compounds induce apoptosis in high concentrations (IC50 >30 ΞΌM) nonetheless, the observed morphological changes of studied cell lines during cell viability assay prompted us to examine their antimetastatic properties. Novel compound MBDR-4 significantly reduces migration and invasiveness of the MDA-MB-231 and A375 cancer cell lines at subapoptotic concentration (5 ΞΌM), which open new avenues for redirecting drug development of selective HDAC6 inhibitors as adjuvant chemotherapeutics, with antimetastatic effects.Π˜ΡΡ‚Ρ€Π°ΠΆΠΈΠ²Π°Ρ‡ΠΈ Ρ‚Ρ€Π΅Π½ΡƒΡ‚Π½ΠΎ ΡƒΠ»Π°ΠΆΡƒ Π²Π΅Π»ΠΈΠΊΠ΅ Π½Π°ΠΏΠΎΡ€Π΅ Ρƒ ΠΈΡΠΏΠΈΡ‚ΠΈΠ²Π°ΡšΠ΅ сСлСктивних ΠΈΠ½Ρ…ΠΈΠ±ΠΈΡ‚ΠΎΡ€Π° хистон Π΄Π΅Π°Ρ†Π΅Ρ‚ΠΈΠ»Π°Π·Π΅ 6 (HDAC6i) 1,2 који Π±ΠΈ ΠΌΠΎΠ³Π»ΠΈ Π΄Π° Π½Π°Ρ’Ρƒ ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΡƒ ΠΏΡ€ΠΈΠΌΠ΅Π½Ρƒ 3 . Ова ΠΈΡΡ‚Ρ€Π°ΠΆΠΈΠ²Π°ΡšΠ° су Π΄Π΅Π»ΠΈΠΌΠΈΡ‡Π½ΠΎ ΠΎΡ‚Π΅ΠΆΠ°Π½Π° услСд нСконзистСнтних ΠΏΡ€Π΅ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈΡ… Ρ€Π΅Π·ΡƒΠ»Ρ‚Π°Ρ‚Π° ΠΎ Ρ›Π΅Π»ΠΈΡ˜ΡΠΊΠΈΠΌ ΠΈ Π±ΠΈΠΎΡ…Π΅ΠΌΠΈΡ˜ΡΠΊΠΈΠΌ ΠΏΡ€ΠΎΠΌΠ΅Π½Π°ΠΌΠ° Π½Π°ΠΊΠΎΠ½ Ρ‚Ρ€Π΅Ρ‚ΠΌΠ°Π½Π° солидних Ρ‚ΡƒΠΌΠΎΡ€Π° HDAC6i(4,5). Наша ΡΡ‚ΡƒΠ΄ΠΈΡ˜Π° ΠΎΠ±ΡƒΡ…Π²Π°Ρ‚Π° ΠΊΠΎΠΌΠΏΡ˜ΡƒΡ‚Π΅Ρ€ΡΠΊΠΈ дизајн ΠΈ синтСзу Ρ‚Ρ€ΠΈ Π½ΠΎΠ²Π° HDAC6 ΠΈΠ½Ρ…ΠΈΠ±ΠΈΡ‚ΠΎΡ€Π°, зајСдно са in vitro Снзимским ΠΈΡΠΏΠΈΡ‚ΠΈΠ²Π°ΡšΠ΅ΠΌ активности Π½Π° сродним ΠΈΠ·ΠΎΡ„ΠΎΡ€ΠΌΠ°ΠΌΠ° HDAC Π΅Π½Π·ΠΈΠΌΠΈΠΌΠ°. АнтинСопластичан Π΅Ρ„Π΅ΠΊΠ°Ρ‚ синтС- тисаних јСдињСња јС испитан in vitro Π½Π° Ρ‡Π΅Ρ‚ΠΈΡ€ΠΈ Ρ‚ΠΈΠΏΠ° Ρ›Π΅Π»ΠΈΡ˜Π° ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ°, Ρ…ΡƒΠΌΠ°Π½ΠΈΠΌ Ρ›Π΅Π»ΠΈΡ˜Π°ΠΌΠ° ΠΊΠ°Ρ€Ρ†ΠΈΠ½ΠΎΠΌΠ° дојкС (MDA-MB-231 ΠΈ MCF-7) ΠΈ Ρ…ΡƒΠΌΠ°Π½ΠΈΠΌ Ρ›Π΅- лијама ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠ° (A-375 ΠΈ 518A2). Π£Ρ‚Π²Ρ€Ρ’Π΅Π½ΠΎ јС Π΄Π° синтСтисана јСдињСња ΠΈΠ½Π΄ΡƒΠΊΡƒΡ˜Ρƒ Π°ΠΏΠΎΠΏΡ‚ΠΎΠ·Ρƒ ΠΏΡ€ΠΈ високим ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΡ˜Π°ΠΌΠ° (IC 50 >30 ΞΌM). Π˜ΡΡ‚ΠΎΠ²Ρ€Π΅ΠΌΠ΅- Π½ΠΎ јС ΡƒΠΎΡ‡Π΅Π½ΠΎ Π΄Π° ΠΎΠ²Π° јСдињСња Π΄ΠΎΠ²ΠΎΠ΄Π΅ ΠΈ Π΄ΠΎ ΠΌΠΎΡ€Ρ„ΠΎΠ»ΠΎΡˆΠΊΠΈΡ… ΠΏΡ€ΠΎΠΌΠ΅Π½Π° Π½Π° Ρ‚Ρ€Π΅- Ρ‚ΠΈΡ€Π°Π½ΠΈΠΌ Ρ›Π΅Π»ΠΈΡ˜Π°ΠΌΠ° Ρ‚ΠΎΠΊΠΎΠΌ ΠΈΠ·Π²ΠΎΡ’Π΅ΡšΠ° тСста виабилности ΡˆΡ‚ΠΎ нас јС усмСри- Π»ΠΎ ΠΊΠ° ΠΈΡΠΏΠΈΡ‚ΠΈΠ²Π°ΡšΡƒ ΡšΠΈΡ…ΠΎΠ²ΠΈΡ… антимСтастатских особина. ЈСдињСњС MBDR-4 снаТно ΠΈΠ½Ρ…ΠΈΠ±ΠΈΡ€Π° ΠΌΠΈΠ³Ρ€Π°Ρ†ΠΈΡ˜Ρƒ ΠΈ инвазивност MDA-MB-231 ΠΈ A375 Ρ›Π΅Π»ΠΈΡ˜Π° ΠΊΠ°Π½- Ρ†Π΅Ρ€Π° Π½Π° ΡΡƒΠ±Π°ΠΏΠΎΠΏΡ‚ΠΎΡ‚ΡΠΊΠΎΡ˜ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΡ˜ΠΈ (5 ΞΌM), ΡˆΡ‚ΠΎ ΠΎΡ‚Π²Π°Ρ€Π° Π½ΠΎΠ²Π΅ могућности Π·Π° ΠΈΡΡ‚Ρ€Π°ΠΆΠΈΠ²Π°ΡšΠ΅ сСлСктивних HDAC6 ΠΈΠ½Ρ…ΠΈΠ±ΠΈΡ‚ΠΎΡ€Π° ΠΊΠ°ΠΎ Π°Π΄Ρ˜ΡƒΠ²Π°Π½Ρ‚Π½ΠΈΡ… Ρ…Π΅ΠΌΠΎΡ‚Π΅- Ρ€Π°ΠΏΠ΅ΡƒΡ‚ΠΈΠΊΠ° са антимСтастатским Π΅Ρ„Π΅ΠΊΡ‚ΠΎΠΌ.ΠšΠ°Π½Ρ†Π΅Ρ€ΠΎΠ»ΠΎΡˆΠΊΠ° ΡΠ΅ΠΊΡ†ΠΈΡ˜Π° Брпског лСкарског Π΄Ρ€ΡƒΡˆΡ‚Π²Π° Serbian Medical Society Oncology Section Π‘Π΅ΠΎΠ³Ρ€Π°Π΄, Π½ΠΎΠ²Π΅ΠΌΠ±Π°Ρ€ 2019 / Belgrade, November 2019 ΠΠΠΠ›Π˜ ΠšΠΠΠ¦Π•Π ΠžΠ›ΠžΠ¨ΠšΠ• Π‘Π•ΠšΠ¦Π˜ΠˆΠ• Π‘Π›Π” ANNALS OF ONCOLOGY SECTION Π—Π±ΠΎΡ€Π½ΠΈΠΊ апстраката / Abstract Boo
    • …
    corecore